Results 231 to 240 of about 788,607 (367)

Exercise training restores longevity‐associated tryptophan metabolite 3‐hydroxyanthranilic acid levels in middle‐aged adults

Acta Physiologica, Volume 241, Issue 5, May 2025.
Abstract Aim Recent pre‐clinical evidence suggests that the tryptophan metabolite 3‐hydroxyanthranilic acid (3‐HAA) and the related enzyme activity along the kynurenine metabolic pathway (KP) are associated with lifespan extension. We aimed to translate these findings into humans and expose exercise training as a potential non‐pharmacological ...
Niklas Joisten, Marcel Reuter, Friederike Rosenberger, Andreas Venhorst, Marie Kupjetz, David Walzik, Alexander Schenk, Adrian McCann, Per Magne Ueland, Tim Meyer, Philipp Zimmer   +10 more
wiley   +1 more source

The Efficacy of Andexanet Alfa for the Reversal of Factor Xa Inhibitors Is Not Influenced by Hemodilution with Different Volume Expanders. [PDF]

J Clin Med
Wienhold J, Rossaint R, Vandeput E, Grottke O.   +3 more
europepmc   +1 more source

Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study. [PDF]

J Clin Med, 2022
Rauch S, Müller HP, Dreyhaupt J, Ludolph AC, Kassubek J, Althaus K.   +5 more
europepmc   +1 more source

Quantitative proteomics identifies plasma protein alterations that associate with metabolic and thrombotic profile changes after bariatric surgery

Diabetes, Obesity and Metabolism, Volume 27, Issue 5, Page 2647-2657, May 2025.
Abstract Objective Roux‐en‐Y gastric bypass (RYGB) surgery has been shown to lead to favourable health outcomes in obese patients. However, the molecular changes that occur and how they relate to clinical measures are poorly understood. Here, we characterise the proteomic alterations that occur in plasma of RYGB patients before and 9 months after ...
Hasnain Ahmed, Marco F. Fernandes, Kazim Abbas, Silvia A. Synowsky, Sally L. Shirran, Ramzi A. Ajjan, Alan J. Stewart   +6 more
wiley   +1 more source

Safety and Efficacy of Oral Direct Factor Xa Inhibitors in Patients With Nephrotic Syndrome: Results From a National Retrospective Study. [PDF]

Kidney Int Rep
Arches C, Jalal-Eddine A, Titeca-Beauport D, Dao M, Lobbedez T, Zaoui P, Masset C, Bertrand D, El Karoui K, Brenier H, Sakhi H, Peiffer B, Audard V, Joher N.   +13 more
europepmc   +1 more source

Synthesis and Evaluation of 1-Arylsulfonyl-3-piperazinone Derivatives as Factor Xa Inhibitors III. Effect of Ring Opening of Piperazinone Moiety on Inhibition

, 2004
Hidemitsu Nishida, Yutaka Miyazaki, Takafumi Mukaihira, Hiroyasu Shimada, Kazuhiro Suzuki, Fumihiko Saitoh, Masashi Mizuno, Tomokazu Matsusue, Atsushi Okamoto, Yoshitaka Hosaka, Miwa Matsumoto, Shuhei Ohnishi, Hidenori Mochizuki   +12 more
openalex   +2 more sources

Comparison of outcomes in patients with intracranial hemorrhage on factor Xa inhibitors versus vitamin K antagonists treated with 4-factor prothrombin complex concentrate

Proceedings, 2018
Sarah Harrison, J. Garrett, Kelsey N Kohman, J. Kline   +3 more
semanticscholar   +1 more source

Utilization of anti-factor Xa levels to guide reversal of oral factor Xa inhibitors in the emergency department. [PDF]

Am J Health Syst Pharm, 2022
Zepeski AE, Faine BA, Merrill AE, Sutamtewagul G, Bhagavathi S.   +4 more
europepmc   +1 more source

Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation [PDF]

, 2010
Hui‐Kyung Jeon, Li‐Ming Lien, Wen-Ter Lai, Hung‐Fat Tse, Wook-Sung Chung, Tsong-Hai Lee, Shih-Ann Chen, Namsik Chung   +7 more
openalex   +1 more source

Incidence and Predictors of Clinical Outcomes in Real-Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow-Up Results of the ANATOLIA-AF Study. [PDF]

Clin Cardiol
Kocabaş U, Ergin I, Sönmez SC, Yavuz V, Murat S, Özdemir IH, Genç Ö, Tüner H, Meriç BK, Aslan O, Dal A, Taşkın U, Şen T, İbişoğlu E, Erdoğan A, Özgeyik M, Demir M, Urgun ÖD, Doğduş M, Çakal S, Çayırlı S, Güler A, Karabulut D, Dalgıç O, Murat B, Karabulut U, Öztekin GMY, Biter Hİ, Sinan ÜY, Barış VÖ, Kaplan M, Altın C, Kıvrak T.   +32 more
europepmc   +1 more source